Expression of E2F-1, Rb and ER in Peripheral Papilloma and Ductal Carcinoma in Situ of the Breast and its Significance

REFERENCES

1. ↵
   1. Ho GH,
   2. Calvano JE,
   3. Bisogna M, et al.

   Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas. Breast Cancer Res Treat 2001;69:115-122.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Carlson CA,
   2. Ethier SP

   . Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells. Radiat Res 2000;154:590-599.

   OpenUrlCrossRefPubMed
3. ↵
   1. Tavassoli FA,
   2. Devilee P

   . Editors IARC Press, Lyon. The WHO classification of tumors of the breast and female genital organs. 2003;10-112.
4. ↵
   1. Page DL,
   2. Jensen RA,
   3. Simpson JF

   . Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol 1998; 2:120-128.

   OpenUrl
5. ↵
   1. Liu FS

   1. Fu XL

   . Histopathologic typing of breast tumors. See: Liu FS Chief Editor, Histopathologic Classification of Tumors of Chinese. Beijing: Scientific and Technical Documents Publishing House. 2001;3:409-411 (Chinese).

   OpenUrl
6. ↵
   1. Niu Y,
   2. Li Y,
   3. Niu RF, et al.

   Correlation of E2F-1 and Rb expression with papillomatosis and ductal carcinoma in situ of the breast. Chin J Oncol 2004;26:290-293 (Chinese).

   OpenUrl
7. ↵
   1. Nielsen- NH,
   2. Loden- M,
   3. Cajander- J, et al.

   G1-S transition defects occur in most breast cancer and predict outcome. Breast Cancer Res Treat 1999;56:105-112.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Zacharatos P,
   2. Kotsinas A,
   3. Evanqelou K, et al.

   Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 2004;203:744-753.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Garcia-Tumon I,
   2. Ricote M,
   3. Ruiz A, et al.

   Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations. Cancer Invest 2006;24:119-125.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Bindels EM,
    2. Lallemand F,
    3. Balkenende A, et al.

    Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 2002;21:8158-8165.

    OpenUrlCrossRefPubMed
11. ↵
    1. Nobert GS,
    2. Kraak MM,
    3. Crawford S

    . Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches. Bull Cancer 2006;93:E59-66.

    OpenUrl
12. ↵
    1. Zheng W,
    2. Zheng J,
    3. Ma L, et al.

    Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma. AP-MIS 2005;113:175-181.

    OpenUrlPubMed
13. ↵
    1. Gewirtz DA,
    2. Di YM,
    3. Ramdolph JK, et al.

    Rb dephosphorylation and suppression of E2F activity in human breast tumor cells exposed to a pharmacological concentration of estradiol. Arch Biochem Biophys 2001; 388:243-252.

    OpenUrlPubMed
14. ↵
    1. Jensen SS,
    2. Madsen MW,
    3. Lukas J, et al.

    Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001;15:1370-1380.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Schuur ER,
    2. Loktev AV,
    3. Sharma M, et al.

    Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 2001;276:33554-33560.

    OpenUrlAbstract/FREE Full Text